Affimed(US:AFMD) globenewswire.com·2024-05-23 21:05Core Insights - The combination of AFM24 and atezolizumab in patients with metastatic EGFR wild-type NSCLC showed a disease control rate of 73.3%, with 11 out of 15 patients achieving disease control, including 4 objective responses (1 complete and 3 partial) [1][2] - The median progression-free survival for the treatment was reported at 5.9 months, with 3 of the 4 responses still ongoing as of the March 18, 2024 data cut-off [1][2] - The study results will be presented at the ASCO annual meeting on June 1, 2024, and a conference call will be held the same day to discuss updated results [1][4][5] Study Details - The AFM24-102 study involved 17 patients with EGFR wild-type NSCLC, with 15 being evaluable for response [2] - All responders had previously shown resistance to checkpoint inhibitor treatments, indicating the potential of AFM24 combined with atezolizumab to enhance the cancer-immunity cycle [2][3] - The study aims to enroll up to 40 patients in the EGFR wild-type cohort and 25 patients in the EGFR mutant cohort [3] Treatment Tolerability - The treatment was well tolerated among heavily pretreated patients, with side effects consistent with known safety profiles of the agents used [3] - The most common side effects included mild to moderate infusion-related reactions and transient increases in liver enzymes [3] Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company focused on leveraging the innate immune system to combat cancer [8] - The company's proprietary ROCK® platform is used to develop its innate cell engagers (ICE®), which target a range of tumors [8] - Affimed is committed to advancing clinical development and exploring combination therapies to improve patient outcomes [3][8]